Nanjing Jingjie Biotechnology

Nanjing Jingjie Biotechnology Co., Ltd., operating as Eaglenos Sciences, is a biotechnology company founded in 2018 that develops, manufactures, and markets diagnostic devices. The company is headquartered in Nanjing, China, and has expanded to establish a research and development base of over 7,500 square meters.

Eaglenos specializes in precise point-of-care testing (POCT) products for home and clinical settings, focusing on chronic diseases like diabetes and cardiovascular conditions. Its product lineup features three main platforms: cartridge testing, paper-strip testing, and dynamic monitoring. Key products include multi-functional monitoring meters for blood glucose, uric acid, lactate, and ketones, as well as blood gas and electrolyte analyzers for acute care settings like ICUs and emergency rooms. These devices are engineered using the company's core technologies in electrochemistry, microfluidics, and signal acquisition.

The company serves both individual users and medical institutions, offering digital data management platforms and integrated health solutions to complement its hardware. Eaglenos generates revenue through the production and sale of its diagnostic devices, wearable monitoring systems, and health management products. The company is privately held and venture capital-backed, having secured a Series A funding round of $22 million in February 2023.

Keywords: point-of-care testing, in-vitro diagnostics, POCT, diagnostic devices, health monitoring, chronic disease management, blood glucose monitoring, electrolyte analyzer, microfluidics, electrochemical detection, blood gas analysis, home care diagnostics, clinical diagnostics, wearable medical devices, self-testing devices, cardiovascular diseases, diabetes management, hyperuricemia